Efficacy of sacubitril valsartan versus enalapril on elderly patients with chronic heart failure with reduced ejection fraction
10.3969/j.issn.1009-0126.2025.05.014
- VernacularTitle:沙库巴曲缬沙坦与依那普利对慢性射血分数减低的心力衰竭老年患者疗效的对比分析
- Author:
Qingqing ZHANG
1
;
Jiao WANG
1
;
Yingxiao DA
1
;
Xin LI
1
Author Information
1. 054000 邢台市中心医院心内科
- Publication Type:Journal Article
- Keywords:
heart failure;
enalapril;
heart function tests;
heart
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2025;27(5):606-610
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the difference in clinical efficacy of sacubitril valsartan(SV)and enalapril in the treatment of elderly patients with chronic heart failure with reduced ejection frac-tion(HFrEF).Methods A total of 126 elderly patients with chronic HFrEF admitted in our de-partment between January 2020 and January 2023 were prospectively recruited and randomly di-vided into control group(enalapril treatment,63 cases)and observation group(SV treatment,63 cases).After 3 months of treatment,the improvement rate of NYHA cardiac function grade,and changes in cardiac function indicators[6-minute walking distance(6MWD),NT-proBNP,LVEDD,LVEF],and echocardiographic indicators[left ventricular myocardial work(Tei)index,stroke volume,cardiac output(CO)]before and after treatment,adverse reactions during treat-ment and prognosis were compared between the two groups.Results The improvement rate of NYHA grade was significantly higher in the observation group than the control group(80.95％vs 65.08％,P＜0.05).The results of 6MWD,LVEF,stroke volume and CO were obviously higher in both groups after treatment than before treatment(P＜0.05).The results of 6MWD,LVEF,stroke volume and CO were notably higher in the observation group than the control group(P＜0.01).The SBP,DBP,NT-proBNP,heart rate,LVEDD and LV Tei index were decreased after treatment in both groups,and those in the observation group were even lower than those in the control group(P＜0.05,P＜0.01).As of April 2024,the readmission rates due to HF was re-markably lower in the observation group than the control group(7.94％vs 20.63％,P＜0.05),but no statistical difference was seen in the mortality or the incidence of adverse reactions be-tween them(P＞0.05).Conclusion SV is superior to enalapril in improving the efficacy,cardiac function and cardiac load of elderly HFrEF patients,with advantages of reducing the incidence of readmission but not increasing adverse reactions.
